Business Wire

AKUR8/AG2R-LA-MONDIALE

29.6.2021 09:02:08 CEST | Business Wire | Press release

Share
AG2R LA MONDIALE Adopts Akur8 to Challenge Its Approach to Health Insurance Pricing

AG2R LA MONDIALE and Akur8 are delighted to announce their collaboration to transform AG2R LA MONDIALE's health insurance pricing process. This move underlines AG2R LA MONDIALE's desire to encourage innovation for the benefit of its policyholders. It also reinforces Akur8's relevance in the health insurance sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005016/en/

Specifically developed for insurance companies, Akur8's solution enhances their pricing process by automating risk and demand modeling, using a proprietary technology powered by transparent artificial intelligence. Akur8 enables insurers to significantly reduce modeling times, speed up time-to-market and increase predictive power of their models, while retaining absolute transparency and control.

With Akur8, AG2R LA MONDIALE is challenging its health insurance products’ pricing approach in order to offer its policyholders fairer, more transparent and more tailored prices.

"We are delighted to be opening this new chapter with AG2R LA MONDIALE. This move underlines their innovative spirit and ability to adapt constantly in order to serve their clients better, while putting digital transformation at the heart of their plans," said Samuel Falmagne, CEO of Akur8.

"This collaboration with AG2R LA MONDIALE marks a significant step forward in Akur8's continuous development. It reinforces the solution's relevance for health insurance and consolidates our presence in France," said Brune de Linares, Chief of Sales at Akur8.

"We are delighted to collaborate with Akur8. We are constantly seeking to provide better support to our policyholders, in an environment that calls for ever more agility and adaptability. This experimentation with Akur8 is a prime example of this approach. We hope that this unique, intuitive and innovative solution will provide value in the key process of pricing," said Anne-Charlotte de Raigniac, Director of actuarial services and medical approvals at AG2R LA MONDIALE.

About AG2R LA MONDIALE:
As a specialist in social and patrimonial protection in France, AG2R LA MONDIALE insures individuals, businesses and professional branches, providing health protection, protecting assets and income, guarding against accidents and preparing for retirement. The Group has over 15 million policyholders and provides day-to-day support to 500,000 businesses. With more than 11,000 employees, AG2R LA MONDIALE has a presence throughout mainland France and beyond. As a partnership with joint, cooperative governance, the Group cultivates a unique social protection model that closely combines profitability and solidarity, performance and social commitment. Every year it spends millions of euros helping vulnerable people and supporting individual and collaborative initiatives.
Stay up to date: www.ag2rlamondiale.fr / @AG2RLAMONDIALE

About Akur8
Akur8 revolutionizes insurance pricing with transparent AI. Akur8 has developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control over the models created, as required by regulators worldwide. Akur8 is the only solution on the market that reconciles the Machine Learning and Actuarial worlds.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye